Cabio Biotech (Wuhan) Co., Ltd. (SHA:688089)
China · Delayed Price · Currency is CNY 19.37
-0.08 (-0.41%)
At close: Feb 13, 2026
Cabio Biotech (Wuhan) Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Net Income | 169.67 | 124.21 | 91.37 | 64.37 | 128.58 | 130.59 |
Depreciation & Amortization | 55.37 | 55.37 | 48.35 | 27 | 23.96 | 26.01 |
Other Amortization | 3.13 | 3.13 | 1.73 | 0.57 | 0.08 | - |
Loss (Gain) From Sale of Assets | 0 | 0 | -0.05 | -0 | - | - |
Asset Writedown & Restructuring Costs | 13.34 | 13.34 | 9.66 | 35.97 | -2.1 | 1.8 |
Loss (Gain) From Sale of Investments | -1.94 | -1.94 | -2.46 | 1.04 | -8.73 | -20.45 |
Provision & Write-off of Bad Debts | -4.61 | -4.61 | 7.03 | 15.67 | 6.12 | 0.03 |
Other Operating Activities | 18.02 | -4.58 | -6.15 | -7.06 | -0.85 | 11.5 |
Change in Accounts Receivable | -0.47 | -0.47 | -45.73 | -61.48 | -47.72 | -9.68 |
Change in Inventory | -39.94 | -39.94 | -39.59 | -9.22 | -4.87 | 2.58 |
Change in Accounts Payable | 29.06 | 29.06 | 7.51 | 100.12 | 8.99 | 3.66 |
Change in Other Net Operating Assets | -2.09 | -2.09 | -2.92 | 14.66 | - | - |
Operating Cash Flow | 241.1 | 173.04 | 68.89 | 176.4 | 103.29 | 145.88 |
Operating Cash Flow Growth | 61.25% | 151.19% | -60.95% | 70.78% | -29.20% | 10.56% |
Capital Expenditures | -180 | -211.6 | -297.68 | -249.47 | -173.43 | -33.1 |
Sale of Property, Plant & Equipment | -0.06 | 0.1 | 0.27 | 0.16 | 0.19 | 0.17 |
Investment in Securities | 20.76 | -15.66 | 2.62 | -97.91 | -88.86 | -66.77 |
Other Investing Activities | 4.54 | 1.14 | 7.49 | 8.69 | 11.72 | 19.22 |
Investing Cash Flow | -154.76 | -226.03 | -287.3 | -338.53 | -250.37 | -80.48 |
Short-Term Debt Issued | - | - | - | 30 | 30 | - |
Long-Term Debt Issued | - | 18.61 | 11 | - | - | - |
Total Debt Issued | 93.24 | 18.61 | 11 | 30 | 30 | - |
Short-Term Debt Repaid | - | - | - | - | -30 | - |
Long-Term Debt Repaid | - | -22.96 | -31.35 | -0.99 | -0.97 | - |
Total Debt Repaid | -18.06 | -22.96 | -31.35 | -0.99 | -30.97 | - |
Net Debt Issued (Repaid) | 75.18 | -4.34 | -20.35 | 29.01 | -0.97 | - |
Issuance of Common Stock | 0.59 | - | 6.39 | - | - | - |
Common Dividends Paid | -34.84 | -34.02 | -36.58 | -39.85 | -39.87 | -60 |
Other Financing Activities | -23.84 | - | 16.53 | - | 1.47 | -3.95 |
Financing Cash Flow | 17.1 | -38.36 | -34.02 | -10.83 | -39.37 | -63.95 |
Foreign Exchange Rate Adjustments | 1.09 | 0.9 | 1.46 | 7.02 | -1.81 | -0.94 |
Net Cash Flow | 104.53 | -90.44 | -250.96 | -165.94 | -188.26 | 0.52 |
Free Cash Flow | 61.11 | -38.55 | -228.79 | -73.07 | -70.14 | 112.78 |
Free Cash Flow Growth | - | - | - | - | - | 3.78% |
Free Cash Flow Margin | 10.24% | -6.94% | -51.55% | -16.86% | -19.98% | 34.87% |
Free Cash Flow Per Share | 0.36 | -0.23 | -1.35 | -0.43 | -0.42 | 0.67 |
Cash Income Tax Paid | 38.94 | 29.66 | 49.04 | 26.62 | 39.54 | 48.93 |
Levered Free Cash Flow | -40.17 | -128.6 | -342.35 | -139.91 | -135.83 | 64.58 |
Unlevered Free Cash Flow | -39.39 | -128.35 | -341.98 | -139.68 | -135.61 | 64.58 |
Change in Working Capital | -11.87 | -11.87 | -80.6 | 38.85 | -43.77 | -3.6 |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.